Advertisement
U.S. markets closed

Vera Therapeutics, Inc. (VERA)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
43.12-0.71 (-1.62%)
At close: 04:00PM EDT
43.00 -0.12 (-0.28%)
After hours: 04:38PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Williams %R

Williams %R

Previous Close43.83
Open43.84
Bid43.00 x 100
Ask43.14 x 200
Day's Range42.38 - 44.44
52 Week Range5.95 - 50.78
Volume652,619
Avg. Volume1,291,168
Market Cap2.348B
Beta (5Y Monthly)1.10
PE Ratio (TTM)N/A
EPS (TTM)-2.25
Earnings DateMay 09, 2024 - May 13, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est48.88
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for VERA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Vera Therapeutics, Inc.
    Daily – Vickers Top Buyers & Sellers for 02/09/2023The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    last yearArgus Research
View more
  • GlobeNewswire

    Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

    Presented positive 72-week data from the Phase 2b ORIGIN clinical trial, setting a new standard in IgAN with no loss of kidney function over the duration of treatmentActively adding sites and enrolling pivotal Phase 3 ORIGIN 3 study of atacicept for the treatment of IgAN; topline data expected in 1H 2025Completed $287.5 million financing, further strengthening the Company’s balance sheet and extending the Company’s expected cash runway through potential approval and commercial launch BRISBANE, C

  • GlobeNewswire

    Vera Therapeutics to Participate at the 44th Annual TD Cowen Health Care Conference

    BRISBANE, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced that the Company’s management team will participate in the 44th Annual TD Cowen Health Care Conference, which is taking place from March 4th to 6th at the Marriott Copley Place in Boston, MA. IgAN Corporate Panel Discussion Details:

  • Simply Wall St.

    Estimating The Fair Value Of Vera Therapeutics, Inc. (NASDAQ:VERA)

    Key Insights Using the 2 Stage Free Cash Flow to Equity, Vera Therapeutics fair value estimate is US$46.59 Vera...